Drug Profile
Research programme: synthetic triacyl compounds - OM Pharma
Alternative Names: OM-197-MP-AC - OM PharmaLatest Information Update: 08 Oct 2020
Price :
$50
*
At a glance
- Originator OM Pharma
- Class
- Mechanism of Action Toll-like receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Hypersensitivity
Most Recent Events
- 30 Sep 2020 OM Pharma has been acquired by Optimus Holding
- 01 May 2014 Discontinued - Preclinical for Cancer in Switzerland (unspecified route)
- 01 May 2014 Discontinued - Preclinical for Hypersensitivity in Switzerland (unspecified route)